Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country

Potentially true Certainty of evidence: low provisional C-ODD-12

Pioglitazone (Actos) raises bladder cancer risk by 63%.

Conclusion: Plausible, small absolute risk from observational data.
  1. Original statement
  2. Scientific assessment
  3. In plain language
  4. Studies on this claim
  5. Regional context
  6. What applies in my country?
  7. References

Original statement

أظهرت دراسة BMJ على 145,806 مريضاً أن بيوغليتازون (أكتوس) يرفع خطر سرطان المثانة 63%.

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Pioglitazone (Actos) raises bladder cancer risk by 63%.

Origin

Source status
Archive editors
Attribution
Archive editors (not Elawady)
Origin
https://eltayebat.com/rule/oral-diabetes-drugs/
Attribution uncertainty
Editorial narrative and study selection written by the archive operators.
Claimed health effect

Bladder cancer

Population concerned

Pioglitazone users

Geographic restriction by Elawady

none found

Scientific assessment

Potentially true – Some evidence points in favour of the statement, but it is not sufficient for a clear judgement.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

Pioglitazone raises bladder cancer by 63%.

2. What is demonstrably correct?

Tuccori et al.: HR 1.63 (1.22-2.19); 121.0 vs 88.9 per 100,000 person-years; duration and dose response; no association for rosiglitazone (A-ODD-03).

3. What is wrong or exaggerated?

'Raises' implies proven causation; the absolute excess is about 32 cases per 100,000 person-years. Pioglitazone also has potential benefits (not reviewed here).

4. What remains unclear?

Causality; consistency across other cohorts (not systematically searched in this audit).

5. Which studies support it?

A-ODD-03.

6. Which studies contradict it?

None reviewed in this audit.

7. What applies to Germany and Europe?

EU labels contraindicate pioglitazone in current or past bladder cancer (not separately fetched).

8. What is known about Egypt?

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. What practical conclusion is appropriate?

A plausible rare risk that is part of prescribing decisions; blood in the urine on pioglitazone should be reported.

Assessment details

Rationale for certainty of evidence

Large population cohort with lag time, dose- and duration-response and a negative control (rosiglitazone) supports a real association; but it is observational, absolute risk difference is small (121 vs 89 per 100,000 person-years) and other large studies have produced mixed results (not reviewed in detail here).

Source quality

Archive editorial citing a population cohort.

Regional transferability

UK data; relevant to Europe.

Individual exceptions

History of bladder cancer or haematuria warrants avoiding pioglitazone.

Regional scope of the claim
general (biological/medical)
Last reviewed
25 October 2026 provisional

In plain language

A large British study found that people using pioglitazone had more bladder cancer, especially after long use at high doses. The extra risk is about 3 cases per 10,000 people per year. This is taken into account by doctors when choosing the drug.

Studies on this claim

Studies supporting the claim (1)

  • Pioglitazone and bladder cancer

    Tuccori M et al.. BMJ 2016 · PMID 27029385 · DOI 10.1136/bmj.i1541
    Cohort studycited by the Tayebat archivefull text checked

    Pioglitazone users had 63% more bladder cancer, about 3 extra cases per 10,000 people per year.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pioglitazone and bladder cancer

    How was the study done?

    Population-based cohort (CPRD), time-varying lagged exposure

    How many people, animals or samples were studied?

    145,806; New users of antidiabetic drugs

    What was actually found?

    HR 1.63 with dose/duration response.

    How large was the observed effect?

    HR 1.63 (1.22-2.19)

    What do the results mean in everyday life?

    Small absolute risk to consider.

    What are the study's limitations?

    Observational; only 54 bladder cancers in pioglitazone users; possible residual confounding or detection (more urine tests).

    What does it say about Elawady's specific claim?

    Supports C-ODD-12, C-ODD-05.

    Do the results apply to Germany and Europe?

    UK data.

    What can explicitly not be concluded from this study?

    Certain causation.

    Scientific details →

Studies contradicting or limiting the claim (0)

No studies in this group.

Studies with mixed or unclear results (0)

No studies in this group.

Regional context

Germany / EU

EU labels contraindicate pioglitazone in current or past bladder cancer (not separately fetched).

Egypt

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

What applies in my country?

General scientific assessment

Potentially true Plausible, small absolute risk from observational data.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Pioglitazone use and risk of bladder cancer: population based cohort study.. Tuccori M et al.. BMJ 2016 · PMID 27029385 · DOI 10.1136/bmj.i1541

← Back to overview